Overview
Dysphagia Palliation in Esophageal Cancer
Registration is closed for this activity.
This educational activity is designed to educate clinicians such as oncologists and gastroenterologists as well as physician-trainees, pharmacists, nurses and allied health professionals involved in the care and management of dysphagia, specifically for patients suffering from esophageal cancer. There are 1700 new cases per year in the U.S. which results in 1600 deaths. Those with esophageal cancer face a high mortality rate and ultimately their major goal is to prolong their life and improve their quality of life. Topics such as screening and diagnosis, managing comorbidities and treatment-related side effects, and palliative care will be covered for oncology specialists to expand their knowledge and transform their practice in cancer care.
This program is designed for oncologists, gastroenterologists, physician-trainees, pharmacists, nurses, and other allied health care professionals who are involved in the care of esophageal cancer patients.
Upon completion of this educational activity, participants will be better able to:
- Discuss the various modalities for management of dysphagia.
- Select the appropriate modality for management of dysphagia in an esophageal cancer patient.
- Explain the goals of palliative treatment in esophageal cancer patients.
Ocean 44
4748 N Goldwater Blvd
Scottsdale, AZ 85251 USA
Click here to view location map
Phone: (480) 867-0044
4748 N Goldwater Blvd
Scottsdale, AZ 85251 USA
Click here to view location map
Phone: (480) 867-0044
6:00 pm - 6:30 pm: Registration
6:30 pm - 7:30 pm: Educational Session
6:30 pm - 7:30 pm: Educational Session
Sponsored by the Academy for Continued Healthcare Learning (ACHL) and Cancer Treatment Centers of America® (CTCA)
Toufic Kachaamy, MD
Gastroenterologist & Advanced Endoscopist
Co-Director, Gastrointestinal Cancer Institute
Director of Endoscopy, Interventional GI and Innovation
Cancer Treatment Centers of America
Goodyear, AZ
Madappa Kundranda, MD, PhD, FACP
Director, Gastrointestinal Oncology Program
Deputy Chief – Division of Medical Oncology
Banner MD Anderson
Gilbert, AZ
Gastroenterologist & Advanced Endoscopist
Co-Director, Gastrointestinal Cancer Institute
Director of Endoscopy, Interventional GI and Innovation
Cancer Treatment Centers of America
Goodyear, AZ
Madappa Kundranda, MD, PhD, FACP
Director, Gastrointestinal Oncology Program
Deputy Chief – Division of Medical Oncology
Banner MD Anderson
Gilbert, AZ
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Toufic Kachaamy, MD (Faculty)
Advisory Board: CSA Medical
Journal Club Member: Boston Scientific Corporation
Advisory Board: CSA Medical
Journal Club Member: Boston Scientific Corporation
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Madappa Kundranda, MD, PhD, FACP (Faculty):
Consultant: Amgen and Bayer
Discussion of Off-Label, Ivestigational, or Experimental Drug/Device Use: None
Madappa Kundranda, MD, PhD, FACP (Faculty):
Consultant: Amgen and Bayer
Discussion of Off-Label, Ivestigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, participants are required to participate in the live activity, complete the evaluation and submit on-site. A certificate will be emailed to participants within 6 weeks. Please be sure to check your junk/spam folders. Due to firewalls, the certificate emails sometimes go there. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Cancer Treatment Centers of America® (CTCA). ACHL is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Part II
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, Dysphagia Palliation in Esophageal Cancer has met the requirements as an MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry & Neurology
Radiology
